阿司匹林治疗ARDS:一项随机、安慰剂对照临床试验
该研究为随机、双盲、分配隐藏、安慰剂对照的2期试验,在5个英国ICU开展,纳入符合柏林定义的ARDS成人患者,1:1随机接受肠内阿司匹林75 mg或安慰剂,最长14天,按血管升压药需求分层。因招募缓慢,在纳入49例(计划60例)后提前终止,阿司匹林组24例、安慰剂组25例。主要终点第7天氧合指数无显著差异(阿司匹林组未校正均值54.4,SD 26.8;安慰剂组42.4,SD 25;均数差12.0;95%CI -6.1至30.1;P=0.19)。阿司匹林未显著影响次要结局,两组不良事件数均为13例(OR 1.04;95%CI 0.56-1.94;P=0.56)。作者认为阿司匹林耐受良好但未改善氧合指数或其他生理结局,当前设计下更大规模试验不可行。
要点
- 在5个英国ICU的ARDS成人患者中,肠内阿司匹林75 mg每日一次最长14天,第7天氧合指数与安慰剂无显著差异(54.4 vs 42.4;均数差12.0;95%CI -6.1至30.1;P=0.19)。
- 阿司匹林未显著影响次要结局(其他呼吸生理标志物),两组不良事件数均为13例(OR 1.04;95%CI 0.56-1.94;P=0.56)。
- 该2期试验因招募缓慢在纳入49例(计划60例)后提前终止,阿司匹林组24例、安慰剂组25例。
- 作者认为阿司匹林耐受良好但未改善氧合指数或其他生理结局,当前设计下更大规模试验不可行。
适用人群与场景
- 符合柏林定义的ARDS成人患者,收治于5个英国ICU;按血管升压药需求分层随机。
诊断标准与关键阈值
- 纳入标准:符合柏林定义的ARDS。
处置流程与药物剂量
- 肠内阿司匹林75 mg,每日一次,最长14天;对照组为安慰剂。
研究设计与关键结果
- 研究类型:随机、双盲(患者与研究者)、分配隐藏、安慰剂对照2期试验,在5个英国ICU开展;采用计算机生成随机序列、可变区组大小、按血管升压药需求分层,1:1随机。
- 样本量:因招募缓慢在纳入49例(计划60例)后提前终止;阿司匹林组24例,安慰剂组25例;意向性治疗分析。
- 主要终点第7天氧合指数:阿司匹林组未校正均值54.4(SD 26.8)vs 安慰剂组42.4(SD 25);均数差12.0;95%CI -6.1至30.1;P=0.19,无显著差异。
- 次要结局:阿司匹林未显著影响次要结局(包括安全性参数及其他呼吸生理标志物)。
- 不良事件:两组均为13例;OR 1.04;95%CI 0.56-1.94;P=0.56。
证据类型、等级与局限
- 证据类型:随机、双盲、分配隐藏、安慰剂对照2期临床试验(RCT)。
- 局限:因招募缓慢提前终止,实际纳入49例(计划60例);作者认为当前设计下更大规模试验不可行。
对床旁实践的改变
- 作者认为阿司匹林耐受良好但未改善氧合指数或其他生理结局;当前设计下更大规模试验不可行。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is no pharmacologic treatment for ARDS. Platelets play an important role in the pathophysiology of ARDS. Preclinical, observational, and clinically relevant models of ARDS indicate aspirin as a potential therapeutic option.
RESEARCH QUESTION: Is enteral aspirin (75 mg, once daily) safe and effective in improving surrogate outcomes in adult patients with ARDS?
STUDY DESIGN AND METHODS: This randomized, double-blind (patient and investigator), allocation-concealed, placebo-controlled phase 2 trial was conducted in five UK ICUs. Patients fulfilling the Berlin definition of ARDS were randomly assigned at a 1:1 ratio to receive enteral aspirin (75 mg) or placebo, for a maximum of 14 days, using a computer-generated randomization schedule, with variable block size, stratified by vasopressor requirement. The primary end point was oxygenation index (OI) on day 7. Secondary outcomes included safety parameters and other respiratory physiological markers. Analyses were by intention to treat.
RESULTS: The trial was stopped early, due to slow recruitment, after 49 of a planned 60 patients were recruited. Twenty-four patients were allocated to aspirin and 25 to placebo. There was no significant difference in day 7 OI [aspirin group: unadjusted mean, 54.4 (SD 26.8); placebo group: 42.4 (SD 25); mean difference, 12.0; 95% CI, -6.1 to 30.1; P = .19]. Aspirin did not significantly impact the secondary outcomes. There was no difference in the number of adverse events between the groups (13 in each; OR, 1.04; 95% CI, 0.56-1.94; P = .56).
INTERPRETATION: Aspirin was well tolerated but did not improve OI or other physiological outcomes; a larger trial is not feasible in its current design.
TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02326350; URL: www.
CLINICALTRIALS: gov.
参考来源
- Toner P, Boyle AJ, McNamee JJ, et al. Aspirin as a Treatment for ARDS: A Randomized, Placebo-Controlled Clinical Trial. Chest. 2021. PMID: 34785236. doi:10.1016/j.chest.2021.11.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。